E. coli BL21(DE3) strains, like Lucigen’s E. cloni® EXPRESS Competent Cells provide reliable expression of many genes cloned into T7 expression vectors (e.g., pET or Lucigen’s pSMART®-cDNA vectors). However, in some cases expression is minimal or not detectable because the recombinant protein, when expressed, is deleterious or lethal to these standard BL21 strains. Examples of such toxic proteins include many membrane proteins, some cytoplasmic proteins, and nucleases. Unfortunately, successful expression of one or more toxic proteins is often important to the experimental goal.
Lucigen’s OverExpress Electrocompetent and Chemically Competent Cells are E. coli strains that are effective in expressing toxic proteins from all classes of organisms, including eubacteria, yeasts, plants, viruses, and mammals. The effectiveness of these new strains in expressing toxic proteins has been validated in more than 350 publications.
The OverExpress strains contain genetic mutations phenotypically selected for conferring tolerance to toxic proteins. The strain C41(DE3) was derived from BL21(DE3). This strain has at least one mutation, which prevents cell death associated with expression of many recombinant toxic proteins. The strain C43(DE3) was derived from C41(DE3) by selecting for resistance to a different toxic protein and can express a different set of toxic proteins to C41(DE3). Figure 1 graphically illustrates the advantages of the OverExpress Competent Cells, compared to standard BL21(DE3) cells, in expressing toxic proteins.
Figure 1. Green Fluorescent Protein (top) or Red Fluorescent Protein (bottom) expressed from a T7 promoter construct that was transformed into C41, BL21, or C43 competent cells spread on IPTG plates to induce protein expression.
Table 1 and Figure 2 summarize transformation effectiveness, tolerance of expression-induced toxicity, and protein expression for T7 expression plasmids coding for a variety of recombinant proteins. These results demonstrate that the OverExpress C41(DE3) and C43(DE3) strains are clearly superior to the parental BL21(DE3) in transformation and expression of toxic proteins.
|Table 1. Comparison of OverExpress C41(DE3) and C43(DE3) cells with the parental strain BL21(DE3) in transformation and expression of heterologous proteins.**|
| Transformation |
Success Rate a
|Expression-induced Toxicity b||Expressing Plasmids c|
|a||Transformation success corresponds to the presence of colonies on LB+ampicillin agar following transformation with a plasmid.|
|b||Expression toxicity corresponds to the absence of colonies on LB+ampicillin+IPTG agar following transformation with a plasmid.|
|c||Expressing plasmids corresponds to observation of a heterologous protein in the total cell pellet on Coomassie-stained SDS-PAGE following growth of a colony in LB+ampicillin medium and induction with IPTG.|
|**||L. Dumon-Seignovert, G. Cariot, and L. Vuillard (2004). Protein Expression and Purification 37, 203-206. Data used with permission.|
Figure 2. Comparison of OverExpress C41(DE3) and C43(DE3) cells with the parental strain BL21(DE3) in transformation and expression of heterologous proteins.**
As in standard BL21(DE3) strains, OverExpress C41(DE3), C41(DE3)pLysS, C43(DE3), and C43 (DE3)pLysS are lysogens of λDE3. These strains carry a chromosomal copy of the T7 RNA Polymerase gene under the control of the lacUV5 promoter. These strains are suitable for production of protein from target genes cloned into T7-driven expression vectors. OverExpress C41(DE3), C41(DE3) pLysS, C43(DE3), and C43(DE3) pLysS are also deficient in the lon and ompT proteases.
OverExpress C41(DE3)pLysS and C43(DE3)pLysS also carry a chloramphenicol-resistant plasmid that encodes T7 lysozyme, which is a natural inhibitor of T7 RNA polymerase. Cells containing pLysS produce a small amount of T7 lysozyme. These strains are used to suppress basal expression of T7 RNA polymerase prior to induction, thus stabilizing recombinants encoding particularly toxic proteins.
It is difficult to predict which of the four OverExpress strains – C41(DE3), C43(DE3), C41(DE3)pLysS, or C43(DE3)pLysS – will work best in expressing a given protein. We recommend initially using the OverExpress ComboPack™ which contains 3 reactions each of the four OverExpress competent cell strains, to determine which one is best for your application. The OverExpress strains are available as electrocompetent or chemically competent cells.
Because there are no intrinsic antibiotic resistances (or plasmids) in either C41(DE3) or C43(DE3), the strains can be differentiated from each other and from BL21(DE3) by transformation with a strain verification vector, pAVD10. pAVD10 contains the uncF gene (encoding the beta-subunit of E. coli ATPase) under the control of the T7 promoter. This plasmid is lethal to BL21(DE3) and to induced C41(DE3), but it is tolerated by C43(DE3) regardless of induction. pAVD10 is provided with OverExpress Cells.
Important Product Use Information
OverExpress Cells are licensed exclusively to Lucigen Corporation by Imaxio S.A. under US Pat. 6,361,966 and others. Purchase of OverExpress Cells is accompanied by a non-exclusive, non-transferable license for research use only. Commercial use requires a separate license available from Imaxio S.A. OverExpress Cells are also sold under a license issued to Lucigen Corporation by Brookhaven Science Associates, LLC (BSA) for research use by noncommercial entities. Commercial entities require a license from BSA even for research use.
OverExpress C41(DE3): F – ompT hsdSB (rB- mB-) gal dcm (DE3)
OverExpress C41(DE3)pLysS: F – ompT hsdSB (rB- mB-) gal dcm (DE3) pLysS (CmR)
OverExpress C43(DE3): F – ompT hsdSB (rB- mB-) gal dcm (DE3)
OverExpress C43(DE3)pLysS: F – ompT hsdSB (rB- mB-) gal dcm (DE3) pLysS (CmR)
Table 1. OverExpress Transformation Efficiencies
|Electrocompetent Cells|| |
> 1 × 1010
> 1 × 109
> 1 × 1010
> 1 × 109
|Chemically Competent Cells|
> 1 × 106
> 1 × 106
> 1 × 106
> 1 × 106